Eden Innovations (ASX: EDE) has reported continued commercial progress across its EdenCrete and OptiBlend product lines, alongside the near-completion of a major balance sheet restructure during the December 2025 quarter.
The company completed a $4.35 million equity raising and materially reduced its debt burden, leaving it better positioned to support sales growth and operational execution.
Eden has reduced total debt by approximately $16m since 30 June 2025 through asset sales, refinancing, and the conversion of shareholder loans.
The company said the strengthened financial position supports its objective of reaching positive cash flow during calendar year 2026.
EdenCrete Sales And Project Activity
Eden reported its third and largest EdenCrete Pz7 order from Holcim Ecuador during the quarter—a US$341,850 order despatched in December and delivered in January.
Holcim has purchased more than $1m of EdenCrete Pz7 since February 2024, with Eden estimating annual sales to the customer could grow to around US$800,000.
EdenCrete Pz7 continued to be specified on major infrastructure and commercial projects in the US, including the Bellview Station Block F development in Denver and the Colorado Department of Transportation I-70 Floyd Hill expansion.
Eden said contractors on these projects have reported consistently strong concrete performance, with enhanced compressive strength and durability attributed to Pz7.
The company also continued EdenCrete Pz7 trials in India with the Central Road Research Institute, targeting highway, bridge, and pavement applications across large-scale infrastructure markets.
OptiBlend Commercial Momentum
OptiBlend sales accelerated in the US during the quarter, driven by growing demand from data centres and industrial customers seeking fuel efficiency and emissions performance.
Eden received nine OptiBlend orders worth US$455,000 during the first four months of FY26, with total US OptiBlend orders in October alone accounting for around 80 per cent of full-year FY25 sales.
OptiBlend revenue received during the quarter totalled US$265,380, with purchase orders awaiting delivery and installation valued at approximately US$674,000 as at 31 December.
Eden US had live OptiBlend quotations issued totalling more than US$4.1m at quarter end, reflecting an expanding pipeline of prospective sales.
The company is also pursuing OptiBlend opportunities across India, Africa, and the Middle East through a combination of direct sales and regional representatives.
Financial Reconstruction
Eden completed the placement of shortfall shares from its entitlement offer during the quarter, raising $4.35m before costs, including $250,000 from major shareholder Noble Energy.
The company used the proceeds to further reduce its high-interest debt, including the repayment and extinguishment of the remaining iBorrow loan balance.
Subsequent to quarter end, Eden secured a $2.2m strategic convertible note investment from a major shareholder, removing remaining quarterly debt servicing obligations.
As at 31 December 2025, Eden held cash and cash equivalents of $3.67m, equating to an estimated funding runway of approximately 2.7 quarters based on recent operating cash outflows.
Improved Operating Leverage
The combination of recurring EdenCrete orders, expanding OptiBlend demand and a materially strengthened balance sheet positions Eden for improved operating leverage.
The company’s focus remains on converting trial programs into repeat commercial sales while maintaining disciplined cost control.
Eden will continue to prioritise markets where durability, sustainability, and performance advantages translate into repeat customer adoption.
The board said the financial reconstruction substantially de-risks the business as it works toward sustained cash flow generation.
